Brainstorm Cell Therapeutics (NASDAQ:BCLI) Cut to Buy at BidaskClub

BidaskClub downgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a strong-buy rating to a buy rating in a report issued on Thursday, BidAskClub reports.

Separately, Maxim Group raised their target price on shares of Brainstorm Cell Therapeutics from $9.00 to $20.00 and gave the stock a buy rating in a report on Wednesday, July 8th.

Shares of Brainstorm Cell Therapeutics stock opened at $13.55 on Thursday. The stock’s fifty day simple moving average is $12.22 and its 200 day simple moving average is $7.34. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $398.93 million, a PE ratio of -11.89 and a beta of 1.12. Brainstorm Cell Therapeutics has a 12 month low of $3.43 and a 12 month high of $17.20.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.09). Analysts predict that Brainstorm Cell Therapeutics will post -1.1 EPS for the current fiscal year.

In other news, COO David Setboun bought 5,000 shares of the company’s stock in a transaction that occurred on Thursday, July 16th. The shares were acquired at an average price of $12.95 per share, with a total value of $64,750.00. Following the transaction, the chief operating officer now owns 55,000 shares in the company, valued at $712,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder International Holdings Ltd Acc sold 3,500 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $13.13, for a total value of $45,955.00. Following the completion of the sale, the insider now owns 135,306 shares in the company, valued at approximately $1,776,567.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,930 shares of company stock valued at $828,557. Company insiders own 21.20% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sunbelt Securities Inc. bought a new position in Brainstorm Cell Therapeutics in the fourth quarter valued at $5,350,000. Strs Ohio acquired a new position in shares of Brainstorm Cell Therapeutics during the 2nd quarter worth about $76,000. Advisor Group Holdings Inc. bought a new position in shares of Brainstorm Cell Therapeutics in the 1st quarter valued at about $40,000. Janney Montgomery Scott LLC acquired a new stake in shares of Brainstorm Cell Therapeutics in the first quarter valued at about $48,000. Finally, Spark Investment Management LLC bought a new stake in Brainstorm Cell Therapeutics during the first quarter worth about $55,000. Institutional investors and hedge funds own 12.59% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Recommended Story: Learning About the VIX – Volatility Index

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.